Eli Lilly and Co. (NYSE:LLY) announced separate licensing and research agreements with South Korea-based Hanmi Pharm and China-based Haisco Pharmaceutical Group, expanding its access to new drug candidates and discovery programs.
The deals come as investors also evaluate positive Phase 3 data for Lilly's cancer therapy Retevmo, even as the stock traded lower in Monday's premarket session.
Lilly Acquires Global Rights To Hanmi's Sonefpeglutide
Hanmi said it entered a licensing agreement with Lilly covering the development, manufacturing, and commercialization of sonefpeglutide, a biologic drug candidate based on its proprietary LAPSCOVERY long-acting technology platform.
The candidate is being evaluated for its potential to promote intestinal growth, reduce inflammation, and support regeneration of the intestinal mucosa. Hanmi is currently conducting a global Phase 2 trial in patients with short bowel syndrome.
